Optimi Health Corp. · CSE:OPTI
Optimi Health — Investor Presentation (January 2022)
23 slides from Optimi Health's investor presentation, January 2022
Slide 1: Championing all-natural medicinal and psychedelic alternatives that OPTIMIZE human potential
Championing all-natural medicinal and psychedelic alternatives that OPTIMIZE human potential JANUARY 2022
Slide 2: Legal Disclaimer
Legal Disclaimer The information contained in this presentation is provided by Optimi Health Corp. (“Optimi” or the “Company”) for informational purposes only and does not constitute an offer to issue or arrange to issue, or the solicitation of an offer to issue, securities of Optimi or other financ
Slide 3: Vision: Farms, Labs, Research, Retail, Leadership
Vision Farms Labs Research Retail Leadership The leading producer and supplier of GMP certified medicinal and psychedelic mushrooms strains seeking commercial opportunities for its products in select markets with favourable regulatory regimes. Developing innovative natural formulations to aid humans
Slide 4: Value Proposition
Value Proposition Optimi Farms Optimi Labs • Two purpose-built facilities • In-house commercial cultivation (10,000 sq. ft. each) processes • Dedicated State-of-the-art GMP • Testing and analytical research & EU GMP-capable • Strain development, breeding, • Fully integrated from cultivation quality
Slide 5: Milestones
Milestones May 27, 2020 July 23, 2020 Aug 12, 2020 Closed Sep 11, 2020 Oct 7, 2020 Nov 19, 2020 Dec 11, 2020 Dec 15, 2020 Incorporation Executed Land Receipt of building Friends/family Quality agreement Submission of Numinous NPN’s Lease Agreement permits and raise $4,490,751 with Canadian Dealer’s
Slide 6: The Problem - Part 1 - Production
Optimi Farms THE PROBLEM - PART 1 - Production • Therapists and patients looking to utilize psychedelics are unable to measure levels of natural psilocybin contained in the mushrooms* • Section 56 exemption holders have no regulated market in which to purchase mushrooms • Consistent dosing when taki
Slide 7: The Solution - Step 1: Facility One
Optimi Farms Facility One: THE SOLUTION - STEP 1 Optimi Developmental Designed as the first state-of-the-art pharmaceutical-grade operation and future global leading GMP certified producer and supplier of psilocybin mushrooms for the ever growing psychedelic research and pharmaceutical industry. Ope
Slide 8: The Solution - Step 1: Facility Two
Optimi Farms Facility Two: THE SOLUTION - STEP 1 Optimi Functional Designed for CTC (Cultivation To Consumer) with an aim towards maximizing margin across the value chain with on-site extract, new product innovation, packaging and ground-up production of high demand functional mushroom varieties suc
Slide 9: Facility License
Optimi Farms Controlled Substance FACILITY LICENSE Research License for Psilocybin Application Facility accepted inspection Optimi Health’s application to Health Canada is underway and if approved, paves the way to pilot cultivation, advanced research and development, NOV DEC 1 FEB DEC 21 Q1 control
Slide 10: Advanced Fungiculture
Optimi Labs Optimi Labs ADVANCED FUNGICULTURE On Site Innovations • Optimi Labs is executing a highly accelerated formulation development and intellectual property (IP) program including but not limited to: • improved bio availability and drug delivery formulations • optimized extraction and ingredi
Slide 11: The Problem - Part 2 - Research
Optimi Labs THE PROBLEM - PART 2 - Research • Big Pharma seeking synthetic therapies for substances that have been used naturally for thousands of years • Complex process limits intellectual property serving the natural psychedelics marketplace • Limited exploration regarding the human optimization
Slide 12: The Solution - Step 2: Optimi Research
Optimi Research Optimi Research THE SOLUTION - STEP 2 We have active research partnerships with: • University of Calgary Clinical Trials and • Hotchkiss Brain Institute • IMPACT Clinical Trial Accelerator Program Drug Development • Numinus Wellness Inc. • Norton Rose Fulbright Canada • Charney IP La
Slide 13: Phase I Dosing Study
Optimi Research Phase I THE SOLUTION - STEP 2 The primary objective for this dose-finding study is to determine the optimal dose of psilocybin to elicit positive mood and cognitive enhancements in healthy Dosing Study volunteers without any concomitant hallucinogenic effects. IMPACT LEAD OPTIMI LEAD
Slide 14: The Psychedelic Market Opportunity
Optimi Research THE PSYCHEDELIC MARKET OPPORTUNITY Medicinal (Current) ANXIETY ADDICTION (high growth segment) (smoking, alcohol, opiods) Anxiety disorders are the most common mental According to the National Survey on Drug Use and illness in the U.S., affecting 40 million adults in Health (NSDUH),
Slide 15: Research Regulatory Environment
Optimi Research Regulatory Environment • 35 Canadians and over twenty health professionals medical access regulations, as well as a government Today Hundreds of have been granted exemptions to possess that would enact them. Canadian patients psilocybin for therapeutic • The psilocybin service and he
Slide 16: The Retail Market Opportunity
Optimi Retail The Problem The Optimi Solution THE RETAIL MARKET OPPORTUNITY There is a supply shortage of North We Build our Few competitors are growing and selling fruiting body mushrooms in American grown high-quality, fruiting Brand Naturally Canada. Optimi’s vertically integrated operation is po
Slide 17: Revenue Generation: Functional Mushrooms
Optimi Retail Functional Mushrooms REVENUE GENERATION that drive the Market 8.44% THE GLOBAL FUNCTIONAL Chaga, Reishi, Lion’s Mane and ANNUAL MUSHROOM MARKET Cordyceps extracts are the most popular GROWTH IS GROWING functional mushrooms. Supplements using Optimi-armed or target sourced products will
Slide 18: Optimi Retail: Nutraceutical Products
Optimi Retail Nutraceutical Products Optimi Health is positioning itself to meet the needs of the rapidly expanding health & wellness sector and to serve consumers looking to prioritize personal optimization through consumption of high quality, natural plant-based products. MINDFUL MUSHROOM IMMUNITY
Slide 19: Summary
Summary Retail Revenue IP Innovation & GMP Opportunity Certified Production Optimi has secured all stages of the supply chain and From supplements and nutraceuticals to future is set to launch its direct-to-consumer e-commerce pharmaceutical opportunities, through a vertically platform designed with
Slide 20: Our Team
Our Team JJ Wilson CHAIRMAN OF THE BOARD Dane Stevens CMO & DIRECTOR Jon Schintler INDEPENDENT DIRECTOR Active CEO and Co-Founder of Ride Cycle Club An entrepreneur with 12 years experience in Jon has a 15year career working in the clean energy and Partner at Very Polite Agency. JJ’s previous intern
Slide 21: Our Advisors
Our Advisors Chip Wilson ADVISOR Edward Safarik ADVISOR Harley Pasternak ADVISOR Chip Wilson is a Canadian businessman Edward is a Member in good standing of Fitness & nutrition specialist; clients include and philanthropist, who has founded the Law Society of British Columbia and Ariana Grande, Lad
Slide 22: Capitalization Table
Capitalization Table Common Shares 70,105,258 Warrants (Strike $0.10, $0.40 & $1.25) 41,867,005 Options (Strike $0.50, $0.60, $0.75 & $1.50) 5,802,000 Restricted Share Rights & Obligation Shares 1,370,625 Fully Diluted 119,144,888 Investor Investor Deck Deck 2022 2021 22
Slide 23: Thank You
OPTIMI HEALTH CORP. 330 – 1122 Mainland Street Vancouver BC V6B 5L1 THANK YOU E. [email protected] T. 778 930 1321